Recombinant Human KRAS Protein，His

KRAS is a prominent member of the RAS gene family, which encodes proteins that act as molecular switches in various cellular processes, including growth, differentiation, and survival. Mutations in the KRAS gene are commonly associated with several types of cancers, particularly pancreatic, colorectal, and lung cancers, making it a critical target for cancer research. The most frequent mutations occur at codons 12, 13, and 61, leading to constitutive activation of KRAS and driving tumorigenesis through aberrant signaling pathways such as the MAPK and PI3K pathways. Due to its central role in oncogenic signaling, KRAS has been a challenging target for drug development, historically considered "undruggable." However, advances in biotechnology and pharmacology have led to the emergence of novel therapeutic strategies aimed at inhibiting mutant KRAS or its downstream effectors. The study of recombinant KRAS proteins, which involves the production of these proteins in vitro using expression systems, has become a pivotal approach to understand the molecular mechanisms of KRAS activation and its interactions with potential inhibitors. Such research not only aids in elucidating the functional impact of specific mutations but also supports the identification and validation of promising drug candidates. Ongoing investigations into KRAS-targeted therapies continue to hold significant promise for improving treatment outcomes in KRAS-mutant cancers, emphasizing the importance of continued research in this area.